Cardiorenal Biomarkers, Canagliflozin, and Outcomes in Diabetic Kidney Disease: The CREDENCE Trial.
James L JanuzziReza MohebiYuxi LiuNaveed SattarHiddo J Lambers HeerspinkEshetu TeferaMuthiah VaduganathanJaved ButlerYshai YavinJingwei LiCarol A PollockVlado PerkovicBruce C NealMichael K HansenPublished in: Circulation (2023)
gov; Unique identifier: NCT02065791.